AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9390983 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill running
Number of subjects: 12
Study 9390983 — intervention group
Group type: COMPARATOR
Intervention: Horizontal running
Number of subjects: 12
Study 8446852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy for 6 to 24 months
Number of subjects: 134
Study 8446852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy
Number of subjects: 134
Study 3094776 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual approach to seeking consent
Number of subjects: 57
Study 3094776 — intervention group
Group type: COMPARATOR
Intervention: Total disclosure of all relevant information
Number of subjects: 57
Study 31843945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study 31843945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study 28985263 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily for 15 weeks
Number of subjects: 80
Study 28985263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28985263 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 80
Study 26932381 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intubation checklist and time out
Number of subjects: 224
Study 26576807 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive thoraco-laparoscopic oesophagectomy (MIO) involving thoracoscopic oesophagectomy and laparoscopic gastric mobilisation with cervical anastomosis.
Number of subjects: 648
Study 26576807 — intervention group
Group type: COMPARATOR
Intervention: Open three-stage transthoracic oesophagectomy involving right thoracotomy and laparotomy with cervical anastomosis.
Number of subjects: 648
Study 26576807 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive thoraco-laparoscopic oesophagectomy (MIO)
Number of subjects: 648
Study 26576807 — intervention group
Group type: COMPARATOR
Intervention: Open three-stage transthoracic oesophagectomy
Number of subjects: 648
Study 23568415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 21
Study 23568415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TM)
Number of subjects: 21
Study 20502296 — intervention group
Group type: COMPARATOR
Intervention: Foley balloon inflated to 30 mL
Number of subjects: 192
Study 20502296 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley balloon inflated to 60 mL
Number of subjects: 192
Study 17823963 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg caffeine
Number of subjects: 74
Study 17823963 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-free solution (control)
Number of subjects: 74
Study 16648613 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified diet with Goami No. 2 rice
Number of subjects: 21
Study 12471278 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (20 mg/kg)
Number of subjects: 101
Study 12471278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 101
Study 12471278 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg)
Number of subjects: 101
Study 12471278 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.2 mg/kg)
Number of subjects: 101
Study 12471278 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 101
Study 9525349 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (3.2 times per week, 50 minutes per session)
Number of subjects: 105
Study 9525349 — intervention group
Group type: EXPERIMENTAL
Intervention: Calisthenics training (2.6 times per week, 50 minutes per session)
Number of subjects: 105
Study 9525349 — intervention group
Group type: COMPARATOR
Intervention: Control (light stretching program once a week)
Number of subjects: 105
Study 7609132 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior pelvic exenteration
Number of subjects: 23
Study 7609132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor resection
Number of subjects: 23
Study 7609132 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 23
Study 7609132 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 23
Study 7609132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic retroperitoneal tumors
Number of subjects: 23
Study 7609132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder and/or prostate tumors
Number of subjects: 23
Study 2254769 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered diet history questionnaire
Number of subjects: 0
Study 2254769 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 0
Study 2254769 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (Intervention)
Number of subjects: 0
Study 140786 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide acetone gel
Number of subjects: 0
Study 140786 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide lotion
Number of subjects: 0
Study 140786 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A acid cream
Number of subjects: 0
Study 30442437 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine administration (1000mg of oral liquid l-carnitine once daily for 8 weeks)
Number of subjects: 0
Study 30442437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no l-carnitine administration)
Number of subjects: 0
Study 30442437 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine administration
Number of subjects: 0
Study 29703223 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) cycling
Number of subjects: 19
Study 29703223 — intervention group
Group type: COMPARATOR
Intervention: Passive range of movements (PROM)
Number of subjects: 19
Study 29703223 — intervention group
Group type: COMPARATOR
Intervention: Passive cycle-ergometry
Number of subjects: 19
Study 29703223 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps electrical stimulation
Number of subjects: 19
Study 27598802 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months initial chemotherapy (CT)
Number of subjects: 2687
Study 27598802 — intervention group
Group type: COMPARATOR
Intervention: 6 months initial chemotherapy (CT)
Number of subjects: 2687
Study 27598802 — intervention group
Group type: COMPARATOR
Intervention: No initial chemotherapy (CT)
Number of subjects: 2687
Study 27598802 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial VI local failures
Number of subjects: 2687
Study 27598802 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial VII local failures
Number of subjects: 2687
Study 27598802 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial VI regional/distant failures
Number of subjects: 2687
Study 27598802 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial VII regional/distant failures
Number of subjects: 2687
Study 24512461 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel (nasal dressing without airway)
Number of subjects: 150
Study 24512461 — intervention group
Group type: COMPARATOR
Intervention: Transseptal suture
Number of subjects: 150
Study 24512461 — intervention group
Group type: COMPARATOR
Intervention: Internal nasal splint
Number of subjects: 150
Study 22098260 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 0
Study 22098260 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with cocaine use disorders
Number of subjects: 0
Study 19129719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 30
Study 19129719 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal ventilation
Number of subjects: 30
Study 19129719 — intervention group
Group type: COMPARATOR
Intervention: Hypoventilation
Number of subjects: 30
Study 19129719 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 17611249 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model from the FOSIDIAL trial
Number of subjects: 397
Study 17611249 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline variables in multivariate model
Number of subjects: 397
Study 17611249 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect associations with CVE
Number of subjects: 397
Study 15673863 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture initiated 30 min before induction (Preinduction)
Number of subjects: 7
Study 15673863 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture initiated after induction (At-induction)
Number of subjects: 7
Study 15673863 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture, electrodes positioned near acupoints)
Number of subjects: 7
Study 11926556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide 0.5 mg
Number of subjects: 8
Study 11926556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9790077 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile (AN69) membrane plus subcutaneous EPO after HD
Number of subjects: 11
Study 9790077 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan membrane plus subcutaneous EPO after HD
Number of subjects: 11
Study 9790077 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69 membrane plus subcutaneous EPO after HD plus intravenous EPO immediately before HD
Number of subjects: 11
Study 9790077 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan membrane plus subcutaneous EPO after HD plus intravenous EPO immediately before HD
Number of subjects: 11
Study 7628284 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 47
Study 7628284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2116156 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. midazolam only
Number of subjects: 39
Study 2116156 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. midazolam with antagonism by flumazenil
Number of subjects: 39
Study 2116156 — intervention group
Group type: EXPERIMENTAL
Intervention: infusion of propofol
Number of subjects: 39
Study 834796 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha enhancement condition
Number of subjects: 40
Study 834796 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha suppression condition
Number of subjects: 40
Study 834796 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 40
Study 30610443 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate plus casein protein hydrolysate (PRO)
Number of subjects: 18
Study 30610443 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate only (CHO)
Number of subjects: 18
Study 28074795 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (GSE) 100 mg every 6 hours orally, 24 hours before operation
Number of subjects: 87
Study 28074795 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 25 mg/kg through CPB during surgery
Number of subjects: 87
Study 28074795 — intervention group
Group type: COMPARATOR
Intervention: Control group with no treatment
Number of subjects: 87
Study 25893978 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐min training session in reaching (experimental group)
Number of subjects: 16
Study 25893978 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 16
Study 22814896 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT + SRP
Number of subjects: 2
Study 22814896 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 2
Study 22059446 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based video-driven computer-tailored approach
Number of subjects: 0
Study 22059446 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based text-driven computer-tailored approach
Number of subjects: 0
Study 22059446 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored generic advice (Control)
Number of subjects: 0
Study 19118788 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular intervention
Number of subjects: 71
Study 19118788 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain/counter‐strain technique
Number of subjects: 71
Study 19118788 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 17971864 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin‐piperaquine
Number of subjects: 522
Study 17971864 — intervention group
Group type: COMPARATOR
Intervention: mefloquine‐artesunate
Number of subjects: 522
Study 15262189 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg)
Number of subjects: 61
Study 15262189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11576098 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting acupuncture before extubation
Number of subjects: 60
Study 11576098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 60
Study 9688727 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 24
Study 9688727 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of estrogen and progesterone therapy
Number of subjects: 24
Study 9688727 — intervention group
Group type: COMPARATOR
Intervention: No hormone replacement therapy (No HRT)
Number of subjects: 24
Study 9688727 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT
Number of subjects: 24
Study 9688727 — intervention group
Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 24
Study 1681781 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone hydrochloride (50 mg/day)
Number of subjects: 10
Study 1681781 — intervention group
Group type: COMPARATOR
Intervention: propoxyphene hydrochloride (260 mg/day)
Number of subjects: 10
Study 1681781 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 7121090 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education program
Number of subjects: 900
Study 7121090 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomized)
Number of subjects: 900
Study 31005396 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of intravenous ketorolac plus oxygen at 15 l/min through a non‐rebreather mask (NRB)
Number of subjects: 136
Study 31005396 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of intravenous ketorolac plus 7 l/min of oxygen through a 60% venturi mask
Number of subjects: 136
Study 31005396 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of intravenous ketorolac plus 4 l/min of oxygen through a nasal cannula
Number of subjects: 136
Study 31005396 — intervention group
Group type: COMPARATOR
Intervention: 30 mg of intravenous ketorolac and room air
Number of subjects: 136
Study 31070473 — intervention group
Group type: COMPARATOR
Intervention: Underweight boys compared to obese boys
Number of subjects: 25321
Study 31070473 — intervention group
Group type: COMPARATOR
Intervention: Healthy weight boys compared to obese boys
Number of subjects: 25321
Study 31070473 — intervention group
Group type: COMPARATOR
Intervention: Overweight boys compared to obese boys
Number of subjects: 25321
Study 31070473 — intervention group
Group type: COMPARATOR
Intervention: Healthy weight girls compared to underweight girls
Number of subjects: 25321
Study 31070473 — intervention group
Group type: COMPARATOR
Intervention: Overweight girls compared to underweight girls
Number of subjects: 25321
Study 31070473 — intervention group
Group type: COMPARATOR
Intervention: Obese girls compared to underweight girls
Number of subjects: 25321
Study 27421767 — intervention group
Group type: EXPERIMENTAL
Intervention: Full access to m4RH
Number of subjects: 0
Study 27421767 — intervention group
Group type: COMPARATOR
Intervention: Limited access to m4RH
Number of subjects: 0
Study 27064274 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox-intervention (kindergarten-based, family-involved intervention)
Number of subjects: 4964
Study 27064274 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4964
Study 24378381 — intervention group
Group type: EXPERIMENTAL
Intervention: Symax™ implant
Number of subjects: 50
Study 24378381 — intervention group
Group type: COMPARATOR
Intervention: Omnifit(®) stem
Number of subjects: 50
Study 21604858 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional adjunctive instruction condition
Number of subjects: 94
Study 21604858 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no institutional adjunctive instruction)
Number of subjects: 94
Study 20056221 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on the Shenmen point (HT7) for 5 weeks
Number of subjects: 50
Study 20056221 — intervention group
Group type: COMPARATOR
Intervention: Light touch on the HT7 points (control)
Number of subjects: 50
Study 18703936 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine plus fluoxetine
Number of subjects: 114
Study 18703936 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 114
Study 15714986 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-alpha reductase inhibitor
Number of subjects: 0
Study 15714986 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 0
Study 15714986 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 12595861 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (0.125 mg/kg) administered twice at 10-minute intervals with UFH (70 U/kg)
Number of subjects: 40
Study 12595861 — intervention group
Group type: COMPARATOR
Intervention: Abciximab (0.125 mg/kg) administered twice at 10-minute intervals with dalteparin (60 IU/kg)
Number of subjects: 40
Study 12595861 — intervention group
Group type: EXPERIMENTAL
Intervention: Receptor occupancy assay and PAC1 binding assay
Number of subjects: 40
Study 10319778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway
Number of subjects: 50
Study 10319778 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 50
Study 9174313 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + Ketamine (P + K)
Number of subjects: 40
Study 9174313 — intervention group
Group type: COMPARATOR
Intervention: Propofol (P)
Number of subjects: 40
Study 9174313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 1586385 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after overnight fast
Number of subjects: 14
Study 1586385 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after a light breakfast
Number of subjects: 14
Study 1586385 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after a heavy breakfast
Number of subjects: 14
Study 1586385 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days (steady state)
Number of subjects: 14
Study 3702224 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 kcal/kg/day
Number of subjects: 6
Study 3702224 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 kcal/kg/day
Number of subjects: 6
Study 3702224 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 kcal/kg/day
Number of subjects: 6
Study 3702224 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 kcal/kg/day
Number of subjects: 6
Study 3702224 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.55 to 0.60 g protein/kg/day
Number of subjects: 6
Study 3702224 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximately 35 kcal/kg/day
Number of subjects: 6
Study 29658822 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training (3 x 90 minutes)
Number of subjects: 286
Study 29658822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 286
Study 29658822 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training
Number of subjects: 286
Study 27680597 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 44
Study 27680597 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 44
Study 27680597 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gabapentin and oxybutynin
Number of subjects: 44
Study 24878745 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic artichoke puree exposure (5-10 times)
Number of subjects: 332
Study 24878745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetened artichoke puree exposure (5-10 times)
Number of subjects: 332
Study 24878745 — intervention group
Group type: EXPERIMENTAL
Intervention: Added energy artichoke puree exposure (5-10 times)
Number of subjects: 332
Study 24878745 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to artichoke puree
Number of subjects: 332
Study 24878745 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a predictor of eating pattern
Number of subjects: 332
Study 24878745 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoyment of food and satiety responsiveness
Number of subjects: 332
Study 22682768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone-misoprostol (n=220) - 200mg mifepristone on day 1 and 800 μg buccal misoprostol followed by placebo 3 hours later on day 2
Number of subjects: 441
Study 22682768 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol-only (n=221) - placebo on day 1 and 1600 μg of misoprostol (2 doses of 800 μg, given 3 hours apart) on day 2
Number of subjects: 441
Study 22682768 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol-only (n=221)
Number of subjects: 441
Study 22682768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone-misoprostol (n=220)
Number of subjects: 441
Study 20689194 — intervention group
Group type: EXPERIMENTAL
Intervention: iso-amyl cyanoacrylate
Number of subjects: 10
Study 20689194 — intervention group
Group type: COMPARATOR
Intervention: 6/0 polyglactin
Number of subjects: 10
Study 17508037 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotection strategies
Number of subjects: 0
Study 16213288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) plus 1 g/d Mycophenolate mofetil (MMF)
Number of subjects: 173
Study 16213288 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC) plus 2 g/d Mycophenolate mofetil (MMF)
Number of subjects: 173